Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Tuesday, August 9, 2022

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Molderizer and Safe Shield

Moderna data shows new booster’s ‘superiority’ against omicron

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...


Placeholder while article actions load

Preliminary data on Moderna’s omicron-targeting coronavirus vaccine booster candidate showed that the shot gives recipients a “superior” antibody response against the variant, Moderna announced Wednesday, expressing hope that the company can make the new shots available by late summer.

The booster candidate, which provided an eightfold rise in immunization against omicron, also increased antibodies against the alpha, beta, gamma and delta variants.

Soon after omicron’s discovery last year, Moderna said it was developing shots specifically designed to fight the variant. Rivals Pfizer and BioNTech announced the same. In April, Moderna released data that showed a booster shot that the company began working on in February 2021, tailored to fight the original version of the virus and the beta variant, increased the level of virus-blocking antibodies against several variants, including omicron, better than a regular booster.

Moderna releases data to support its fall vaccine strategy

Data from the recent clinical trial, which involved 437 participants, showed that Moderna’s omicron-targeting booster would probably provide longer protection against variants a month after administration when compared with earlier versions of its coronavirus vaccine, Moderna said, making it the company’s “lead candidate for a Fall 2022 booster.” It will submit the data to regulators in the coming weeks.

The booster “was generally well-tolerated,” with side effects comparable to earlier boosters, the company said.

New daily coronavirus infections are slowly climbing in the United States. The country recorded a 38 percent uptick in new cases during the past week, according to figures compiled by The Washington Post, as protection from booster shots and previous infections wanes and as more people go about their lives without masks.

Globally, new cases are still declining after the omicron variant triggered tens of millions of new cases worldwide, driving up infections to peaks during the winter.

Independent vaccine experts advised the Food and Drug Administration this week to approve a coronavirus vaccine developed by the Maryland biotechnology company Novavax, potentially widening immunization options for Americans.

Novavax’s shots are protein-based — an older but more familiar technology than the mRNA-based shots produced by Moderna or Pfizer and BioNTech. This could persuade the millions of American vaccine holdouts who feel nervous about the mRNA shots to get immunized, vaccine experts say. It is unclear when the new shots would be available.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...

Related Articles

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...